TPTirtha Pandya

Tirtha Pandya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tirtha Pandya has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • A. Feroz

    Department of Nephrology and Transplantation Medicine, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Centre and Dr H.L. Trivedi Institute of Transplantation Sciences, Ahmedabad, Gujarat, India

    1 shared publication
  • A.V. Vanikar

    Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Centre and Dr H.L. Trivedi Institute of Transplantation Sciences, Ahmedabad, Gujarat, India

    1 shared publication
  • D. Saboo

    Department of Nephrology and Transplantation Medicine, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Centre and Dr H.L. Trivedi Institute of Transplantation Sciences, Ahmedabad, Gujarat, India

    1 shared publication
  • Dona Susan Mathew

    Department of Microbiology, Amrita Institute of Medical Science and Research Centre, Amrita Vishwa Vidyapeetham, Kochi 608204, India

    1 shared publication
  • Hargovind L. Trivedi

    Department of Nephrology and Transplantation Medicine, Institute of Kidney Diseases and Research Centre (IKDRC)-Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS), Ahmedabad, Gujarat, India

    1 shared publication
  • Het Pandya

    Public Health Research Institute (PHRI) Center, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA

    1 shared publication

Latest Publications

  • Open Access

    An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines

    by Dona Susan Mathew, Tirtha Pandya, Het Pandya, Yuzen Vaghela, Selvakumar Subbian

    The Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has significantly impacted the health and socioeconomic status of humans worldwide. Pulmonary infection of SARS-CoV-2 results in exorbitant viral replication and associated onset of inflammatory cytokine storm and disease pathology in various internal organs. However, the etiopathogenesis of SARS-CoV-2 infection is not fully understood. Currently, there are no targeted therapies available to cure COVID-19, and most patients are treated empirically with anti-inflammatory and/or anti-viral drugs, based on the disease symptoms. Although several types of vaccines are currently implemented to control COVID-19 and prevent viral dissemination, the emergence of new variants of SARS-CoV-2 that can evade the vaccine-induced protective immunity poses challenges to current vaccination strategies and highlights the necessity to develop better and improved vaccines. In this review, we summarize the etiopathogenesis of SARS-CoV-2 and elaborately discuss various types of vaccines and vaccination strategies, focusing on those vaccines that are currently in use worldwide to combat COVID-19 or in various stages of clinical development to use in humans.


  • Postrenal Transplant Hemolytic Uremic Syndrome/Thrombotic Microangiopathy: Ahmedabad Experience

    by K.R. Goplani, A.V. Vanikar, P.R. Shah, M. Gumber, A. Feroz, H.V. Patel, P. Kasat, J. Falodia, D. Saboo, K. Kaswaan, et al.